MTOR and renal cell carcinoma: m6A-modified TRAF1 mRNA overexpression obviously activated AKT/mTOR/HIF-1α/VEGFA signaling pathway to facilitate angiogenesis, thus promoting sunitinib resistance in RCC (162).